Page 1 15:08 <golam shameem> 06/01/2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12	APR 26	PROMT: New display field available
NEWS 13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14	APR 26	LITALERT now available on STN
NEWS 15	APR 27	NLDB: New search and display fields available
NEWS 16	May 10	PROUSDDR now available on STN
NEWS 17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18	May 12	EXTEND option available in structure searching
NEWS 19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20	May 17	FRFULL now available on STN
NEWS 21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS 22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10670668

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:50:54 ON 01 JUN 2004

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:51:06 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAY 2004 HIGHEST RN 688001-12-9
DICTIONARY FILE UPDATES: 31 MAY 2004 HIGHEST RN 688001-12-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10670668.str



chain nodes :
12 13 14 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 15 16 17 18 19 20 23 24 25 26 27 28
chain bonds :
1-6 3-27 5-12 9-13 13-14 13-22 14-17 14-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17
17-18 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
1-2 1-5 1-6 2-3 9-13 13-14 14-21
exact bonds :
3-4 3-27 4-5 5-12 13-22 14-17
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17 17-18 18-19 19-20 23-24
23-28 24-25 25-26 26-27 27-28
isolated ring systems :
containing 1 : 6 : 15 : 23 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:51:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      5 TO ITERATE

100.0% PROCESSED       5 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:51:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     49 TO ITERATE

100.0% PROCESSED      49 ITERATIONS                         11 ANSWERS
SEARCH TIME: 00.00.01

L3            11 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.63

FILE 'CAPLUS' ENTERED AT 14:51:35 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Jun 2004 VOL 140 ISS 23
FILE LAST UPDATED: 31 May 2004 (20040531/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:22869 CAPLUS
DOCUMENT NUMBER: 138:89806
TITLE: Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease
INVENTOR(S): Ingraham, Richard H.; Proudfoot, John R.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022929	A1	20030130	US 2002-172457	20020614
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092567	A1	20040513	US 2003-670668	20030925

PRIORITY APPLN. INFO.: US 2001-302066P P 20010629
US 2002-172457 A1 20020614
WO 2002-US18752 W 20020614

OTHER SOURCE(S): MARPAT 138:89806
GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

IT **251656-41-4P 251656-54-9P 251656-61-8P**
251656-70-9P 251656-71-0P 483342-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease)

RN 251656-41-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-54-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-61-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylsulfinyl)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-70-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:784082 CAPLUS
DOCUMENT NUMBER: 132:22963
TITLE: Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2 production inhibitors
INVENTOR(S): Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermmann, Mary Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962885	A1	19991209	WO 1999-US12295	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
CA 2332957	AA	19991209	CA 1999-2332957	19990603
AU 9942299	A1	19991220	AU 1999-42299	19990603
JP 2002516909	T2	20020611	JP 2000-552097	19990603
US 6506747	B1	20030114	US 1999-324933	19990603

PRIORITY APPLN. INFO.: US 1998-88154P P 19980605
WO 1999-US12295 W 19990603

OTHER SOURCE(S): MARPAT 132:22963
GI



I

AB Title compds. [I; R = R4Z1Z; R1,R3 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepared Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H](II; R5 = H) was amidated by cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

IT **251656-33-4P 251656-39-0P 251656-41-4P**
251656-54-9P 251656-61-8P 251656-65-2P
251656-67-4P 251656-68-5P 251656-70-9P
251656-71-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 251656-33-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-39-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-bromo-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-41-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-54-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-61-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylsulfinyl)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-65-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-methoxy-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-67-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-68-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(dimethylamino)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-70-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.40	173.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.39	-1.39

FILE 'REGISTRY' ENTERED AT 15:02:19 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAY 2004 HIGHEST RN 688001-12-9
DICTIONARY FILE UPDATES: 31 MAY 2004 HIGHEST RN 688001-12-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10670668a.str



chain nodes :
12 13 14 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 15 16 17 18 19 20
chain bonds :
1-6 5-12 9-13 13-14 13-22 14-17 14-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17
17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-6 2-3 9-13 13-14 14-21
exact bonds :
3-4 4-5 5-12 13-22 14-17
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 6 : 15 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS

L5 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10670668a.str



chain nodes :
12 13 14 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 15 16 17 18 19 20
chain bonds :
1-6 5-12 9-13 13-14 13-22 14-17 14-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17
17-18 18-19 19-20
exact/norm bonds :

10670668

1-2 1-5 1-6 2-3 9-13 13-14 14-21
exact bonds :
3-4 4-5 5-12 13-22 14-17
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 6 : 15 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 15:02:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 529 TO 1351
PROJECTED ANSWERS: 8 TO 329

L7 8 SEA SSS SAM L6

=> s l6 sss full
FULL SEARCH INITIATED 15:03:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 807 TO ITERATE

100.0% PROCESSED 807 ITERATIONS 76 ANSWERS
SEARCH TIME: 00.00.01

L8 76 SEA SSS FUL L6

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	328.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.39

FILE 'CAPLUS' ENTERED AT 15:03:10 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jun 2004 VOL 140 ISS 23
FILE LAST UPDATED: 31 May 2004 (20040531/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 15:03:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 529 TO 1351
PROJECTED ANSWERS: 8 TO 329

L9 8 SEA SSS SAM L6

L10 4 L9

=> d his

10670668

```
     (FILE 'HOME' ENTERED AT 14:50:54 ON 01 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 14:51:06 ON 01 JUN 2004
L1              STRUCTURE UPLOADED
L2            1 S L1
L3           11 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:51:35 ON 01 JUN 2004
L4            2 S L3

     FILE 'REGISTRY' ENTERED AT 15:02:19 ON 01 JUN 2004
L5              STRUCTURE UPLOADED
L6              STRUCTURE UPLOADED
L7            8 S L6
L8           76 S L6 SSS FULL

     FILE 'CAPLUS' ENTERED AT 15:03:10 ON 01 JUN 2004
              S L6

     FILE 'REGISTRY' ENTERED AT 15:03:14 ON 01 JUN 2004
L9            8 S L6

     FILE 'CAPLUS' ENTERED AT 15:03:14 ON 01 JUN 2004
L10           4 S L9

=> s l8 sss full
L11           7 L8

=> FIL REGISTRY
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                1.31     330.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -1.39

FILE 'REGISTRY' ENTERED AT 15:04:48 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 MAY 2004  HIGHEST RN 688001-12-9
DICTIONARY FILE UPDATES:  31 MAY 2004  HIGHEST RN 688001-12-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html
```

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	331.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.39

FILE 'CAPLUS' ENTERED AT 15:05:22 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jun 2004 VOL 140 ISS 23
FILE LAST UPDATED: 31 May 2004 (20040531/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 14:50:54 ON 01 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 14:51:06 ON 01 JUN 2004
L1   STRUCTURE UPLOADED
L2   1 S L1
L3   11 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:51:35 ON 01 JUN 2004
L4   2 S L3

     FILE 'REGISTRY' ENTERED AT 15:02:19 ON 01 JUN 2004
L5   STRUCTURE UPLOADED
L6   STRUCTURE UPLOADED
L7   8 S L6
L8   76 S L6 SSS FULL

     FILE 'CAPLUS' ENTERED AT 15:03:10 ON 01 JUN 2004
              S L6

     FILE 'REGISTRY' ENTERED AT 15:03:14 ON 01 JUN 2004
L9   8 S L6

     FILE 'CAPLUS' ENTERED AT 15:03:14 ON 01 JUN 2004
L10   4 S L9
L11   7 S L8 SSS FULL

     FILE 'REGISTRY' ENTERED AT 15:04:48 ON 01 JUN 2004

     FILE 'CAPLUS' ENTERED AT 15:05:22 ON 01 JUN 2004

=> d l10 ibib abs hitstr tot

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:851793 CAPLUS
DOCUMENT NUMBER: 136:5986
TITLE: Preparation of azole inhibitors of cytokine production
INVENTOR(S):   Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.;
                          Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar,
                          David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun;
                          Sciotti, Richard J.; Wagenaar, Frank L.
PATENT ASSIGNEE(S):   USA
SOURCE: U.S. Pat. Appl. Publ., 124 pp.
                          CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001044445	A1	20011122	US 1999-289155	19990408

PRIORITY APPLN. INFO.: US 1999-289155 19990408
OTHER SOURCE(S): MARPAT 136:5986
GI



I



II

AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph, the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) production and cellular proliferation in stimulated human T cell lines or human peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepared General procedures for preparation of compds. I were described. Thus, the title compound II was prepared

IT **245746-11-6P 245746-99-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole inhibitors of cytokine production)

RN 245746-11-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-

yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:658115 CAPLUS
DOCUMENT NUMBER: 133:238010
TITLE: Preparation of pyrazole derivatives as blockers of calcium release-activated calcium channel (CRACC)
INVENTOR(S): Kubota, Koichi; Yoshimura, Noriko; Okamoto, Yoshinori; Yonetoku, Yasuhiro; Naito, Makoto; Ishikawa, Atsushi; Takeuchi, Makoto
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000256358	A2	20000919	JP 1999-62900	19990310

PRIORITY APPLN. INFO.: JP 1999-62900 19990310
OTHER SOURCE(S): MARPAT 133:238010
GI



I

AB The title compds. (I; ring D = pyrazolyl optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, or haloalkyl, lower alkylene-cycloalkyl, lower alkylene-O-lower alkyl, cycloalkyl, O-lower alkyl, CO2H, lower alkoxycarbonyl, and halo; ring B = phenylene or optionally lower-substituted bivalent monocyclic aromatic heterocyclic ring; X = NR1CO, CONR1, NR1SO2, SO2NR1; wherein R1 = H, OH, lower alkyl, O-lower alkyl, lower alkyl-carbonyl; Y = bond, CO, lower alkylene, or lower alkenylene; ring A = Ph having at least one substituent selected from HO, O-lower alkyl, and F, or optionally substituent mono-, bi-, or tricyclic condensed heteroaryl; provided that when Y is a bond, ring A represents a group other than heteroaryl selected from thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyridyl, pyrazinyl, and isoquinolyl) and pharmaceutically acceptable salts thereof are prepared These compds. exhibit the inhibitory activity against CRACC and the production of interleukin-2 and are useful for the prevention or treatment of allergies,

inflammations, and autoimmune diseases. Thus, 2,1,3-benzoxadiazole-5-carbonyl chloride and Et3N were successively added to a mixture of 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline and CH2Cl2 and stirred at room temperature for 8.5 h to give N-[(2,1,3-benzoxadiazol-5-yl)carbonyl]-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline. Preferred compds. I inhibited thapsigargin-stimulated increase in calcium concentration with IC50 of ≤1 μM and the production of interleukin-2 with IC50 of ≤0.1 μM in Jurkat cell.

IT **245746-99-0P 292610-08-3P 292610-93-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as blockers of calcium release-activated calcium channel and inhibitors of interleukin-2 production)

RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 292610-08-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 292610-93-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:784082 CAPLUS
DOCUMENT NUMBER: 132:22963
TITLE: Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2 production inhibitors
INVENTOR(S): Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermmann, Mary Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962885	A1	19991209	WO 1999-US12295	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
CA 2332957	AA	19991209	CA 1999-2332957	19990603
AU 9942299	A1	19991220	AU 1999-42299	19990603
JP 2002516909	T2	20020611	JP 2000-552097	19990603
US 6506747	B1	20030114	US 1999-324933	19990603

PRIORITY APPLN. INFO.: US 1998-88154P P 19980605
WO 1999-US12295 W 19990603

OTHER SOURCE(S): MARPAT 132:22963
GI



I

AB Title compds. [I; R = R4Z1Z; R1,R3 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepared Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H] (II; R5 = H) was amidated by cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

IT **251655-88-6P 251656-27-6P 251656-65-2P 251657-74-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 251655-88-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-

yl]phenyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 251656-27-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(tetrahydro-2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-65-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-methoxy-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-74-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(2-naphthalenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:659365 CAPLUS
DOCUMENT NUMBER: 131:271873
TITLE: Preparation of pyrazoles and triazoles as inhibitors of cytokine production
INVENTOR(S): Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Wagenaar, Frank L.; Sciotti, Richard J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951580	A1	19991014	WO 1999-US7766	19990408
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327185	AA	19991014	CA 1999-2327185	19990408
AU 9933879	A1	19991025	AU 1999-33879	19990408
EP 1068187	A1	20010117	EP 1999-915341	19990408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002510679	T2	20020409	JP 2000-542301	19990408

PRIORITY APPLN. INFO.: US 1998-56996 A 19980408
WO 1999-US7766 W 19990408

OTHER SOURCE(S): MARPAT 131:271873
GI



I



II

AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R2 = H, alkyl cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2, alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepared and tested as cytokine production inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors. Thus, the title compound II was prepared

IT **245746-11-6P 245746-99-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrazoles and triazoles as inhibitors of cytokine production)

RN 245746-11-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l11 ibib abs hitstr tot

L11 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:203827 CAPLUS
DOCUMENT NUMBER: 140:259189
TITLE: Novel crystals
INVENTOR(S): Kubota, Hirokazu; Iwaoka, Kiyoshi; Yamaguchi, Sou; Yokota, Masaki
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020433	A1	20040311	WO 2003-JP10769	20030826

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-246341 A 20020827

AB Crystals of 4,6-dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having an excellent calcium release-dependent calcium channel inhibitory effect and an excellent IL-2 production inhibitory activity are obtained. It is found out that this compound occurs in two crystal polymorphisms both of which are appropriate as starting materials for producing medicinal compns.

IT **669769-47-5P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystals of 4,6-dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide)
RN 669769-47-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:22869 CAPLUS
DOCUMENT NUMBER: 138:89806
TITLE: Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
INVENTOR(S): Ingraham, Richard H.; Proudfoot, John R.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022929	A1	20030130	US 2002-172457	20020614
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092567	A1	20040513	US 2003-670668	20030925

PRIORITY APPLN. INFO.: US 2001-302066P P 20010629
US 2002-172457 A1 20020614
WO 2002-US18752 W 20020614

OTHER SOURCE(S): MARPAT 138:89806
GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

IT **251656-41-4P 251656-54-9P 251656-61-8P**
251656-70-9P 251656-71-0P 483342-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease)

RN 251656-41-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-54-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-61-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylsulfinyl)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-70-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:851793 CAPLUS
DOCUMENT NUMBER: 136:5986
TITLE: Preparation of azole inhibitors of cytokine production
INVENTOR(S): Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Sciotti, Richard J.; Wagenaar, Frank L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 124 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001044445	A1	20011122	US 1999-289155	19990408

PRIORITY APPLN. INFO.: US 1999-289155 19990408
OTHER SOURCE(S): MARPAT 136:5986
GI



I



II

AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph,

the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) production and cellular proliferation in stimulated human T cell lines or human peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepared General procedures for preparation of compds. I were described. Thus, the title compound II was prepared

IT **223499-45-4P**, N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-pyridinecarboxamide **245745-96-4P** **245745-97-5P** **245745-98-6P** **245746-11-6P** **245746-93-4P** **245746-99-0P** **245747-12-0P** **245747-14-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole inhibitors of cytokine production)

RN 223499-45-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-96-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245745-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)



RN 245746-11-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 245747-12-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5,6-dichloro- (9CI) (CA INDEX NAME)



RN 245747-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:658115 CAPLUS
DOCUMENT NUMBER: 133:238010
TITLE: Preparation of pyrazole derivatives as blockers of calcium release-activated calcium channel (CRACC)
INVENTOR(S): Kubota, Koichi; Yoshimura, Noriko; Okamoto, Yoshinori; Yonetoku, Yasuhiro; Naito, Makoto; Ishikawa, Atsushi; Takeuchi, Makoto
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000256358	A2	20000919	JP 1999-62900	19990310

PRIORITY APPLN. INFO.: JP 1999-62900 19990310
OTHER SOURCE(S): MARPAT 133:238010
GI



I

AB The title compds. (I; ring D = pyrazolyl optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, or haloalkyl, lower alkylene-cycloalkyl, lower alkylene-O-lower alkyl, cycloalkyl, O-lower alkyl, CO2H, lower alkoxycarbonyl, and halo; ring B = phenylene or optionally lower-substituted bivalent monocyclic aromatic heterocyclic ring; X = NR1CO, CONR1, NR1SO2, SO2NR1; wherein R1 = H, OH, lower alkyl, O-lower alkyl, lower alkyl-carbonyl; Y = bond, CO, lower alkylene, or lower alkenylene; ring A = Ph having at least one substituent selected from HO, O-lower alkyl, and F, or optionally substituent mono-, bi-, or tricyclic condensed heteroaryl; provided that when Y is a bond, ring A represents a group other than heteroaryl selected from thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyridyl, pyrazinyl, and isoquinolyl) and pharmaceutically acceptable salts thereof are prepared These compds. exhibit the inhibitory activity against CRACC and the production of interleukin-2 and are useful for the prevention or treatment of allergies, inflammations, and autoimmune diseases. Thus, 2,1,3-benzoxadiazole-5-carbonyl chloride and Et3N were successively added to a mixture of 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline and CH2Cl2 and stirred at room temperature for 8.5 h to give N-[(2,1,3-benzoxadiazol-5-yl)carbonyl]-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline. Preferred compds. I inhibited thapsigargin-stimulated increase in calcium concentration with IC50 of
≤1 μM and the production of interleukin-2 with IC50 of ≤0.1 μM in Jurkat cell.

IT **245745-97-5P 245745-98-6P 245746-93-4P**
245746-99-0P 292610-08-3P 292610-12-9P
292610-14-1P 292610-18-5P 292610-32-3P
292610-48-1P 292610-52-7P 292610-56-1P
292610-63-0P 292610-64-1P 292610-65-2P
292610-66-3P 292610-67-4P 292610-68-5P
292610-69-6P 292610-74-3P 292610-93-6P
292610-94-7P 292610-95-8P 292610-96-9P
292610-97-0P 292610-98-1P 292611-02-0P
292611-03-1P 292611-04-2P 292611-05-3P
292611-06-4P 292611-09-7P 292611-10-0P
292611-11-1P 292611-12-2P 292611-13-3P
292611-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as blockers of calcium release-activated calcium channel and inhibitors of interleukin-2 production)

RN 245745-97-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245745-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)



RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 292610-08-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 292610-12-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,2-dihydro-2-thioxo- (9CI) (CA INDEX NAME)



RN 292610-14-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 292610-18-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 292610-32-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 292610-48-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 292610-52-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 292610-56-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 292610-63-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[methyl(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 292610-64-1 CAPLUS
CN [1(2H),2'-Bipyridine]-3'-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 292610-65-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(butylmethylamino)- (9CI) (CA INDEX NAME)



RN 292610-66-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)



RN 292610-67-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-[[2-(diethylamino)ethyl]ethylamino]- (9CI) (CA INDEX NAME)



RN 292610-68-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 292610-69-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 292610-74-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(methylthio)- (9CI) (CA INDEX NAME)



RN 292610-93-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 292610-94-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 292610-95-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(diethylamino)- (9CI) (CA INDEX NAME)



RN 292610-96-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(butylethylamino)- (9CI) (CA INDEX NAME)



RN 292610-97-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 292610-98-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 292611-02-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(diethylamino)- (9CI) (CA INDEX NAME)



RN 292611-03-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[[2-(diethylamino)ethyl]ethylamino]- (9CI) (CA INDEX NAME)



RN 292611-04-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 292611-05-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 292611-06-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 292611-09-7 CAPLUS
CN [1(2H),2'-Bipyridine]-5'-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 292611-10-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 292611-11-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-[methyl(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 292611-12-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 292611-13-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)



RN 292611-14-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:784082 CAPLUS
DOCUMENT NUMBER: 132:22963
TITLE: Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2 production inhibitors
INVENTOR(S): Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermmann, Mary Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962885	A1	19991209	WO 1999-US12295	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
CA 2332957	AA	19991209	CA 1999-2332957	19990603
AU 9942299	A1	19991220	AU 1999-42299	19990603
JP 2002516909	T2	20020611	JP 2000-552097	19990603
US 6506747	B1	20030114	US 1999-324933	19990603

PRIORITY APPLN. INFO.: US 1998-88154P P 19980605
WO 1999-US12295 W 19990603
OTHER SOURCE(S): MARPAT 132:22963
GI



I

AB Title compds. [I; R = R4Z1Z; R1,R3 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepared Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H] (II; R5 = H) was amidated by cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

IT **223499-45-4P 245745-97-5P 245746-93-4P**
251655-88-6P 251655-92-2P 251655-95-5P
251656-20-9P 251656-25-4P 251656-27-6P
251656-33-4P 251656-35-6P 251656-38-9P
251656-39-0P 251656-41-4P 251656-54-9P
251656-60-7P 251656-61-8P 251656-65-2P
251656-67-4P 251656-68-5P 251656-70-9P
251656-71-0P 251656-74-3P 251656-78-7P
251656-80-1P 251656-81-2P 251656-82-3P
251656-84-5P 251656-89-0P 251657-19-9P

251657-20-2P 251657-21-3P 251657-24-6P
251657-68-8P 251657-74-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 223499-45-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 251655-88-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 251655-92-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 251655-95-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo-2-chloro- (9CI) (CA INDEX NAME)



RN 251656-20-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-25-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-ethyl-5-(trifluoromethyl)-1H-pyrazol-1-

yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-27-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(tetrahydro-2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-33-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-35-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(2-thiazolyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-38-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-ethoxy-5-(trifluoromethyl)-1H-pyrazol-1-

yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-39-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-bromo-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-41-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-54-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-60-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(methoxymethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-61-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylsulfinyl)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-65-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-methoxy-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-67-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-68-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(dimethylamino)-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-70-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-74-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-propyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-78-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-[5-(3-pyridinyl)-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-80-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-[5-(4-pyridinyl)-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-81-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-[5-(5-pyrimidinyl)-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-82-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(5-bromo-2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-84-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(2-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-89-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(4-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-19-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3-[5-[2-[4-(dimethylamino)phenyl]ethenyl]-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-20-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-[5-[2-(4-pyridinyl)ethenyl]-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-21-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-[5-[2-(4-methyl-5-thiazolyl)ethenyl]-2-furanyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-24-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-68-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-cyclopentyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-74-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(2-naphthalenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:659365 CAPLUS
DOCUMENT NUMBER: 131:271873
TITLE: Preparation of pyrazoles and triazoles as inhibitors of cytokine production
INVENTOR(S): Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Wagenaar, Frank L.; Sciotti, Richard J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951580	A1	19991014	WO 1999-US7766	19990408

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2327185	AA	19991014	CA 1999-2327185	19990408	
AU 9933879	A1	19991025	AU 1999-33879	19990408	
EP 1068187	A1	20010117	EP 1999-915341	19990408	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2002510679	T2	20020409	JP 2000-542301	19990408	

PRIORITY APPLN. INFO.: US 1998-56996 A 19980408
WO 1999-US7766 W 19990408

OTHER SOURCE(S): MARPAT 131:271873

GI



I



II

AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R2 = H, alkyl cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2, alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepared and tested as cytokine production inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors. Thus, the title compound II was prepared

IT **223499-45-4P 245745-96-4P 245745-97-5P**
245745-98-6P 245746-11-6P 245746-93-4P
245746-99-0P 245747-12-0P 245747-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrazoles and triazoles as inhibitors of cytokine production)

RN 223499-45-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-96-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245745-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)



RN 245746-11-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 245747-12-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5,6-dichloro- (9CI) (CA INDEX NAME)



RN 245747-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:271338 CAPLUS
DOCUMENT NUMBER: 130:311815
TITLE: Preparation of pyrazole derivatives as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 (IL-2) production
INVENTOR(S): Kubota, Hirokazu; Yonetoku, Yasuhiro; Sugasawa, Keizou; Funatsu, Masashi; Kawazoe, Souichirou; Toyoshima, Akira; Okamoto, Yoshinori; Ishikawa, Jun; Takeuchi, Makoto
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919303	A1	19990422	WO 1998-JP4583	19981012
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9887139	A1	19990429	AU 1998-87139	19980929
AU 751139	B2	20020808		
BR 9803883	A	20000516	BR 1998-3883	19981006
RU 2185381	C2	20020720	RU 1998-118557	19981009
CA 2304979	AA	19990422	CA 1998-2304979	19981012
AU 9894593	A1	19990503	AU 1998-94593	19981012
EP 1024138	A1	20000802	EP 1998-947818	19981012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
MX 9808433	A	20000930	MX 1998-8433	19981012
TW 495498	B	20020721	TW 1998-87116918	19981012
CN 1218046	A	19990602	CN 1998-121354	19981013
CN 1107671	B	20030507		

JP 11240832	A2	19990907	JP 1998-290734		19981013
US 6348480	B1	20020219	US 2000-529131		20000407
NO 2000001907	A	20000609	NO 2000-1907		20000412
US 2001011090	A1	20010802	US 2001-773736		20010202
PRIORITY APPLN. INFO.:			JP 1997-279093	A	19971013
			WO 1998-JP4583	W	19981012
			US 2000-529131	A3	20000407

OTHER SOURCE(S): MARPAT 130:311815

GI



I



II

AB Pyrazole derivs. represented by general formula [I; ring D = pyrazolyl optionally substituted by 1-3 substituents selected from alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, cycloalkylalkyl, alkoxyalkyl, cycloalkyl, alkoxy, CO2H, alkoxycarbonyl, and halo; ring B = phenylene, a nitrogen-containing, divalent, saturated ring group, or an optionally alkylated, monocyclic, divalent heteroarom. ring group; X = -NR1-CR2R3-, -CR2R3-NR1-, -NR1-SO2-, -SO2-NR1- or -CR4:CR5-; wherein R1 = H, OH, alkyl, alkoxy, alkylcarbonyl; R2, R3 = H or alkyl or R2R3 = O or S; R4, R5 = H, halo, lower haloalkyl; A = (1) Ph optionally having one or more substituents, (2) mono-, di- or tricyclic fused heteroaryl optionally having one or more substituents, (3) cycloalkyl optionally having one or more substituents, (4) a nitrogen-containing, saturated ring group optionally having one or more substituents, (5) lower alkenyl optionally having one or more substituents, (6) lower alkynyl optionally having one or more substituents, or (7) alkyl optionally having one or more substituents; or A and X are combined together to represent 1-pyrrolidinylcarbonyl, pyrazolidinylcarbonyl, piperidinocarbonyl, piperazinylcarbonyl, morpholinocarbonyl, 3,4-2H-1,4-benzoxazin-4-ylcarbonyl, or indolylcarbonyl] are prepared Also claimed are medicinal compns., in particular, calcium release-dependent calcium channel inhibitors, IL-2 production inhibitors, and therapeutics or preventives for allergies, inflammations, or autoimmune diseases, bronchial asthma, or rheumatoid arthritis for containing the above compds. I as the active ingredients. Thus, 4-methylthiazole-5-carboxylic acid was condensed with 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in 1,2-dichloroethane at room temperature overnight to give the title compound, 4'-pyrazolylthiazole-5-carboxanilide derivative (II). II in vitro showed IC50 of ≤1 μM μg/mL for inhibiting the production of IL-2 in Jurkat cells.

IT **223499-45-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as calcium release-dependent calcium

channel inhibitors and inhibitors of interleukin-2 production for treatment and prevention of diseases)

RN 223499-45-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:50:54 ON 01 JUN 2004)

FILE 'REGISTRY' ENTERED AT 14:51:06 ON 01 JUN 2004
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 11 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:51:35 ON 01 JUN 2004
L4 2 S L3

FILE 'REGISTRY' ENTERED AT 15:02:19 ON 01 JUN 2004
L5 STRUCTURE UPLOADED
L6 STRUCTURE UPLOADED
L7 8 S L6
L8 76 S L6 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:03:10 ON 01 JUN 2004
S L6

FILE 'REGISTRY' ENTERED AT 15:03:14 ON 01 JUN 2004
L9 8 S L6

FILE 'CAPLUS' ENTERED AT 15:03:14 ON 01 JUN 2004
L10 4 S L9
L11 7 S L8 SSS FULL

FILE 'REGISTRY' ENTERED AT 15:04:48 ON 01 JUN 2004

FILE 'CAPLUS' ENTERED AT 15:05:22 ON 01 JUN 2004

=> s l11 and thu
137 THU
2158280 THUS
2158402 THU
(THU OR THUS)
L12 6 L11 AND THU

```
=> s l12 and py<=2001
      21548647 PY<=2001
L13           5 L12 AND PY<=2001

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    57.71     388.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.62      -9.01

STN INTERNATIONAL LOGOFF AT 15:07:39 ON 01 JUN 2004
```